THANK YOU TO THE MDS/SDH COVID-19 TASK FORCE!
Milan Anadkat, MD – email@example.com
Steven T. Chen, MD, MPH – firstname.lastname@example.org
Lindy Fox, MD – email@example.com
Joanna Harp, MD – firstname.lastname@example.org
Joseph F. Merola, MD, MMSc – email@example.com
Robert Micheletti, MD – firstname.lastname@example.org
Vinod Nambudiri, MD – email@example.com
Helena Pasieka, MD – firstname.lastname@example.org
Misha Rosenbach, MD – email@example.com
Michi M. Shinohara, MD – firstname.lastname@example.org
If you have particular questions you would like us to address or challenges faced in the care of your medical dermatology or hospital dermatology patients, please submit your questions via the link below, so we can assist in finding solutions for our members.
~~ May 12, 2020 ~~
Medical Dermatology Society & Society of Dermatology Hospitalists COVID-19 Mini-symposium II
Thursday, May 19, 2020
7:30 -9:00 pm ET / 6:30-8:00 pm Central / 5:30-7:00 pm Mountain / 4:30-6:00 pm Pacific
Thank you for the robust turnout out our first COVID-19 mini-symposium. We had consistently ~500 active participants and over 560 unique log-ins, and a wide-ranging discussion about Covid-19 skin manifestations, management of inpatient and urgent outpatient conditions, and considerations re: immunosuppressives in the pandemic era.
We are proud to announce a second MDS/SDH joint COVID-19 mini-symposium based on the most common questions that arose out of the prior meeting. We hope you will join us for our second virtual mini-symposium via Zoom (hosted by Harvard).
COVID-19 Mini-symposium Agenda
Times noted are in Eastern Time Zone
7:30 PM – Welcome
7:35 PM – Interferonopathies and how they may relate to COVID-19: Ed Cowen, MD, NIH
7:55 PM – An update on Testing: PCR, Antibodies, what they mean, and how to interpret results: Marlys Fassett, MD, PhD, University of California, San Francisco
8:15 PM – Pernio-like lesions (“Covid-toes”), Kawasaki, and Covid-19 from a Pediatric Perspective: Amy Paller, MD, Northwestern University, Feinberg School of Medicine
8:35 PM – Q&A and Open Discussion
Please submit questions via the RSVP link in advance or via the chat function during the presentations, and we will address questions at the end from members.
~~ April 27, 2020 ~~
Medical Dermatology Society & Society of Dermatology Hospitalists COVID-19 Mini-symposium I
Thursday, April 30, 2020
7:00-8:30 pm Eastern / 6:00-7:30 pm Central / 5:00-6:30 pm Mountain / 4:00-5:30 pm Pacific
The COVID-19 pandemic has dramatically, rapidly altered the world, including the practice of dermatology. The MDS/SDH COVID-19 Joint Task Force has heard from members a request for updates regarding cutaneous issues in patients with COVID-19, particularly on those issues pertaining to the care of hospitalized patients, skin findings in patients with COVID-19, and the management of immunosuppressive agents during the time of COVID-19.
COVID-19 Mini-symposium Agenda
7:00 – 7:05 PM – Welcome
7:05 – 7:25 PM – Skin manifestations in patients with COVID-19
7:25 – 7:35 PM – Urgent dermatology consults in the era of COVID-19
7:35 – 7:45 PM – Management of immunosuppressive agents during COVID-19
7:45 – 8:30 PM – Panel discussion Q&A (MDS/SDH COVID-19 Task Force)
Please submit questions via the chat function during the presentations, and we will address questions at the end from members.
~~ April 15, 2020 ~~
MDS/SDH AHTF Updates on Skin Findings of COVID-19 and COVID Registries
We hope you and your families are well. In an ongoing effort to provide you with useful resources during the COVID-19 pandemic, we would like to highlight the following:
Cutaneous Involvement in COVID: Manifestations and Workup
Increasingly, dermatologists caring for patients with COVID in the United States and abroad have recognized cutaneous manifestations occurring in these patients. Whether these are directly virally-mediated or an immunologic response to infection remains to be elucidated.
Thus far, the following cutaneous manifestations have been reported
- Morbilliform exanthem (may occur at any time in the disease course, nonspecific)
- Livedoid eruption
- Retiform purpura in acral locations and on buttocks
- Pernio like lesions on fingers and toes
- Seems more common in children and young adults (including late)
- Covid PCR may be negative depending on time of presentation
AAD COVID-19 Dermatology Registry
The AAD has launched an international registry to track patients who
- Are diagnosed with (or suspected of having) COVID and have dermatologic manifestations, or
- Have underlying dermatologic disease and become diagnosed with COVID-19
- Any healthcare provider can enter cases. via the link to the registry
- Click to review the email from the AAD regarding the AAD COVID-19 Registry
Hidradenitis Suppurativa COVID Registry
- The Global HS COVID Registry has been launched as an international collaborative effort to improve the care of hidradenitis suppurativa patients during the COVID-19 global crisis by capturing data on risks, treatments and outcomes of pediatric and adult COVID-19-infected HS patients
- The registry is looking for confirmed COVID-19 cases a minimum of 7 days after COVID-19 diagnosis to study outcomes. Link: https://hscovid.ucsf.edu
We appreciate the feedback we have received to our sharing of resources , and look forward to continue to hear from you at any time.
~~ March 30, 2020 ~~
As COVID-19 has dramatically escalated in its impact across the country over the last several weeks and upended the practice of medicine in multiple ways, we seek to be a resource for our membership during this challenging time. Recognizing that members of the MDS and SDH take care of some of the sickest and most complex patients within our specialty, we sought to identify resources to aid our members in tackling several patient- and practice-level questions related to medical and inpatient dermatology. We realize that during this period there is a constant flow of new and rapidly changing information. While we will endeavor to keep our recommendations up-to-date, we encourage members to refer to cdc.gov, the AAD member site, and state and local guidelines for information specific to your particular location.
We formed a MDS/SDH COVID-19 Task Force to review and collect information to share with you. We have compiled the following resources which may help with patient care in the coming weeks:
- An approach to systemic therapeutics in the era of COVID
- An approach to triaging inpatient consults
- An approach to triaging urgent and non-urgent outpatients
- A list of conditions to consider for in-person or urgent evaluation
- An email that can be customized to send to patients on systemic therapeutics
Links to resources can be found below, and as additional information becomes available, we will continue to share resources with you.
Finally, we wish all our members good health and safety as you continue to care for patients in great need of your expertise, insights, and compassion.